Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R6RO
|
|||
| Former ID |
DAP000293
|
|||
| Drug Name |
Mianserin
|
|||
| Synonyms |
Mianserina; Mianserine; Mianserinum; Mianseryna; Norval; Tolvan; Tolvon; Mianserin Monohydrochloride; Mianseryna [Polish]; Bolvidon (TN); Mianserin (INN); Mianserin [INN:BAN]; Mianserina [INN-Spanish]; Mianserine [INN-French]; Mianserinum [INN-Latin]; Norval (TN); Tolvin (TN); Tolvon (TN); 1,2,3,4,10,14b-Hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine; 2-Methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Depression [ICD-11: 6A70-6A7Z; ICD-9: 311] | Approved | [1], [2] | |
| Therapeutic Class |
Antidepressants
|
|||
| Company |
GlaxoSmithKline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H20N2
|
|||
| Canonical SMILES |
CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42
|
|||
| InChI |
1S/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3
|
|||
| InChIKey |
UEQUQVLFIPOEMF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 24219-97-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5025442, 7979983, 8152618, 11336019, 11361258, 11364714, 11367276, 11369838, 11373110, 11374958, 11378002, 11462230, 11466127, 11467247, 11484722, 11485733, 11489019, 11491651, 11493074, 11495624, 14848151, 26752015, 29223290, 46508096, 47291183, 47365243, 47440310, 47515362, 47515363, 47589044, 47736534, 47810801, 47885463, 48035179, 48110499, 48110500, 48334548, 48416276, 49698341, 49962249, 50104682, 56464297, 57322182, 74414799, 85209455, 85787314, 85787904, 90341017, 92308680, 92719300
|
|||
| ChEBI ID |
CHEBI:51137
|
|||
| ADReCS Drug ID | BADD_D01454 | |||
| SuperDrug ATC ID |
N06AX03
|
|||
| SuperDrug CAS ID |
cas=024219974
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2 receptor (5HT2R) | Target Info | Antagonist | [3], [4], [5], [6] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 135). | |||
| REF 2 | Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39. | |||
| REF 3 | 5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6. | |||
| REF 4 | 5-HT2 and 5-HT3 receptors in the lateral parabrachial nucleus mediate opposite effects on sodium intake. Neuroscience. 2007 Jun 8;146(4):1453-61. | |||
| REF 5 | Lack of effect of some dopamine and non-dopamine receptor ligands on amphetamine-induced changes in the rat brain neuropeptide Y system. Pharmacol Rep. 2005 Nov-Dec;57(6):850-5. | |||
| REF 6 | 5-HT2 receptor antagonists given in the acute withdrawal from daily cocaine injections can reverse established sensitization. Eur J Pharmacol. 2002 Oct 25;453(2-3):255-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.